TNF and rheumatoid arthritis: For instance, TNF inhibitors, both antibody- and receptor-Ig–based biologics, have strong disease-attenuating efficacy in rheumatoid arthritis (RA), psoriasis, and IBD, with a clinical response limited to 30–40% of subjects.